Drug Trial Radar · NCT00152386
A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Dec 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
950
Actual
Start
Feb 2005
Primary completion
Oct 2006
Study completion Oct 2006
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Sep 9, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.
Conditions
- Rheumatoid Arthritis
Interventions
Certolizumab pegol (CDP870)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the efficacy of CDP870 in combination with Methotrexate in the treatment of Rheumatoid Arthritis and prevention of structural damage by measuring the ACR20 response at week 24 and change from Baseline
Locations
76 sites in 13 countries. Site status is shown where the registry gives one.
Site not named
Huntsville, Alabama
Site not named
Paradise Valley, Arizona
Site not named
La Jolla, California
Site not named
San Diego, California
Site not named
Denver, Colorado
Site not named
Danbury, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Aventura, Florida
Site not named
Ocala, Florida
Site not named
Orlando, Florida
Site not named
Sarasota, Florida
Site not named
Tampa, Florida
Site not named
Coeur d'Alene, Idaho
Site not named
Springfield, Illinois
Site not named
Wichita, Kansas
Site not named
Wheaton, Maryland
Site not named
St Louis, Missouri
Site not named
Lincoln, Nebraska
Site not named
Charlotte, North Carolina
Site not named
Cleveland, Ohio
Site not named
Dayton, Ohio
Site not named
Duncansville, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Austin, Texas
Site not named
Dallas, Texas
Site not named
San Antonio, Texas
Site not named
Capital Federal, Argentina
Site not named
Córdoba, Argentina
Site not named
Camperdown, Australia
Site not named
Coffs Harbour, Australia
Site not named
Cotton Tree, Australia
Site not named
Malvern, Australia
Site not named
Shenton Park, Australia
Site not named
Victoria Park, Australia
Site not named
Westmead, Australia
Site not named
Wooloongabba, Australia
Site not named
Antwerp, Belgium
Site not named
Brussels, Belgium
Site not named
Liège, Belgium
Site not named
Merksem, Belgium
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.